These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 29543500)

  • 1. Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection and treatment implications.
    Sherry N; Howden B
    Expert Rev Anti Infect Ther; 2018 Apr; 16(4):289-306. PubMed ID: 29543500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Chen T; Xu W; Yu K; Zeng W; Xu C; Cao J; Zhou T
    Microb Drug Resist; 2021 Mar; 27(3):401-409. PubMed ID: 32721272
    [No Abstract]   [Full Text] [Related]  

  • 4. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
    Scudeller L; Righi E; Chiamenti M; Bragantini D; Menchinelli G; Cattaneo P; Giske CG; Lodise T; Sanguinetti M; Piddock LJV; Franceschi F; Ellis S; Carrara E; Savoldi A; Tacconelli E
    Int J Antimicrob Agents; 2021 May; 57(5):106344. PubMed ID: 33857539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
    Sader HS; Huband MD; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
    [No Abstract]   [Full Text] [Related]  

  • 6. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.
    Vasoo S; Cunningham SA; Cole NC; Kohner PC; Menon SR; Krause KM; Harris KA; De PP; Koh TH; Patel R
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7842-6. PubMed ID: 26392487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial resistance and treatment: an unmet clinical safety need.
    Bassetti M; Russo A; Carnelutti A; La Rosa A; Righi E
    Expert Opin Drug Saf; 2018 Jul; 17(7):669-680. PubMed ID: 29897796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance.
    Shields RK; Nguyen MH; Hao B; Kline EG; Clancy CJ
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17).
    Sader HS; Castanheira M; Mendes RE; Flamm RK
    J Antimicrob Chemother; 2018 Nov; 73(11):3053-3059. PubMed ID: 30060117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes.
    Dallow J; Otterson LG; Huband MD; Krause KM; Nichols WW
    Int J Antimicrob Agents; 2014 Dec; 44(6):552-6. PubMed ID: 25293578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
    Falcone M; Paterson D
    J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organisms.
    Wenzler E; Lee M; Wu TJ; Meyer KA; Shields RK; Nguyen MH; Clancy CJ; Humphries RM; Harrington AT
    J Antimicrob Chemother; 2019 Mar; 74(3):633-638. PubMed ID: 30534964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration.
    Papadopoulos A; Ribera A; Mavrogenis AF; Rodriguez-Pardo D; Bonnet E; Salles MJ; Dolores Del Toro M; Nguyen S; Blanco-García A; Skaliczki G; Soriano A; Benito N; Petersdorf S; Pasticci MB; Tattevin P; Tufan ZK; Chan M; O'Connell N; Pantazis N; Kyprianou A; Pigrau C; Megaloikonomos PD; Senneville E; Ariza J; Papagelopoulos PJ; Giannitsioti E;
    Int J Antimicrob Agents; 2019 Mar; 53(3):294-301. PubMed ID: 30395988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement.
    ; Guan X; He L; Hu B; Hu J; Huang X; Lai G; Li Y; Liu Y; Ni Y; Qiu H; Shao Z; Shi Y; Wang M; Wang R; Wu D; Xie C; Xu Y; Yang F; Yu K; Yu Y; Zhang J; Zhuo C
    Clin Microbiol Infect; 2016 Mar; 22 Suppl 1():S15-25. PubMed ID: 26627340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ceftazidime/avibactam in various combinations for the treatment of experimental osteomyelitis in rabbits caused by OXA-48-/ESBL-producing Escherichia coli.
    Davido B; Crémieux AC; Vaugier I; De Truchis P; Hamami K; Laurent F; Saleh-Mghir A
    J Antimicrob Chemother; 2023 May; 78(5):1211-1218. PubMed ID: 36897329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011).
    Flamm RK; Sader HS; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):233-8. PubMed ID: 25128477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.